{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006997","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.435080+00:00","generated_at":"2026-05-16T11:14:58.662354+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd reports preliminary Q4 2025 revenue $17.2M, VYD2311 Phase 3 trial initiated, top-line data mid-2026","bullets":["Preliminary Q4 2025 PEMGARDA net product revenue of $17.2M, up 25% YoY from $13.8M and 31% QoQ from $13.1M.","Ending 2025 cash and cash equivalents of $226.7M after raising over $200M in 2H 2025.","Initiated DECLARATION Phase 3 pivotal trial of VYD2311 for COVID prevention; top-line data expected mid-2026.","Fast Track designation for VYD2311 granted by FDA in December 2025.","Selected potential best-in-class RSV antibody candidate VBY329; IND readiness targeted for 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006997","json":"https://secwatch.observer/filing/0001193125-26-006997.json","markdown":"https://secwatch.observer/filing/0001193125-26-006997.md","text":"https://secwatch.observer/filing/0001193125-26-006997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/0001193125-26-006997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/d93103d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:14:58.662354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}